We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
The upcoming report from Halozyme Therapeutics (HALO - Free Report) is expected to reveal quarterly earnings of $2.29 per share, indicating an increase of 33.1% compared to the year-ago period. Analysts forecast revenues of $480.68 million, representing an increase of 35.7% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Halozyme Therapeutics metrics that are routinely monitored and predicted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenues- Revenues under collaboration agreements' should arrive at $26.30 million. The estimate points to a change of +9.6% from the year-ago quarter.
Analysts predict that the 'Revenues- Product sales, net' will reach $127.75 million. The estimate suggests a change of +35.6% year over year.
It is projected by analysts that the 'Revenues- Royalties' will reach $326.63 million. The estimate indicates a year-over-year change of +38.4%.
Analysts' assessment points toward 'Product sales, net- Device partnered product sales' reaching $12.18 million. The estimate indicates a year-over-year change of +28.3%.
The combined assessment of analysts suggests that 'Product sales, net- Bulk rHuPH20 sales' will likely reach $45.22 million. The estimate points to a change of +39.2% from the year-ago quarter.
According to the collective judgment of analysts, 'Product sales, net- Proprietary product sales' should come in at $65.64 million. The estimate suggests a change of +25.7% year over year.
Shares of Halozyme Therapeutics have experienced a change of +17.2% in the past month compared to the -2% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), HALO is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
The upcoming report from Halozyme Therapeutics (HALO - Free Report) is expected to reveal quarterly earnings of $2.29 per share, indicating an increase of 33.1% compared to the year-ago period. Analysts forecast revenues of $480.68 million, representing an increase of 35.7% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Halozyme Therapeutics metrics that are routinely monitored and predicted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenues- Revenues under collaboration agreements' should arrive at $26.30 million. The estimate points to a change of +9.6% from the year-ago quarter.
Analysts predict that the 'Revenues- Product sales, net' will reach $127.75 million. The estimate suggests a change of +35.6% year over year.
It is projected by analysts that the 'Revenues- Royalties' will reach $326.63 million. The estimate indicates a year-over-year change of +38.4%.
Analysts' assessment points toward 'Product sales, net- Device partnered product sales' reaching $12.18 million. The estimate indicates a year-over-year change of +28.3%.
The combined assessment of analysts suggests that 'Product sales, net- Bulk rHuPH20 sales' will likely reach $45.22 million. The estimate points to a change of +39.2% from the year-ago quarter.
According to the collective judgment of analysts, 'Product sales, net- Proprietary product sales' should come in at $65.64 million. The estimate suggests a change of +25.7% year over year.
View all Key Company Metrics for Halozyme Therapeutics here>>>Shares of Halozyme Therapeutics have experienced a change of +17.2% in the past month compared to the -2% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), HALO is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .